Seven Corners Issues Follow-Up on Allergan (AGN), Reiterates Sell Rating Due to Non-GAAP Accounting Concerns, Sees 50% Downside in Stock

April 18, 2017

  • Allergan’s So-Called "Performance Net Income" Is A Cash-Flow Measure, Not A Net Income Measure.

  • Allergan Has Thumbed its Nose At The SEC, Which Has Warned Against This Type of Misleading Non-GAAP Metric.

  • To Bridge the GAAP (Pun Intended), We Propose a Realistic Calculation of Allergan’s True Economic Earnings.

  • Even Using Extremely Generous Assumptions, Based on Our Non-GAAP Earnings Calculations We Estimate Allergan’s Valuation to be $117 Per Share, Indicating 50% Expected Downside For Its Common Shares. 


To find a PDF containing our full AGN writeup, please visit our Research section (link here).



Please reload

Featured Posts

CCUR Holdings: 2019 Annual Meeting Trip Report

November 11, 2019

Please reload

Recent Posts
Please reload

Please reload

50 Vanderbilt Ave, 4th Fl, New York, New York 10017

Content © 2016 Seven Corners Capital Management, LLC. All rights reserved.

  • RSS Social Icon
  • Twitter Social Icon
  • SA